+- +-

+-User

Welcome, Guest.
Please login or register.
 
 
 
Forgot your password?

+-Stats ezBlock

Members
Total Members: 9
Latest: Titan
New This Month: 0
New This Week: 0
New Today: 0
Stats
Total Posts: 475
Total Topics: 473
Most Online Today: 1
Most Online Ever: 5546
(September 01, 2021, 03:27:01 am)
Users Online
Members: 0
Guests: 1
Total: 1

Author Topic: Arimidex vs Nolvadex  (Read 25 times)

0 Members and 0 Guests are viewing this topic.

ROAD2HARDCOREIRON

  • Trade Count: (0)
  • Administrator
  • Hero Member
  • *****
  • Posts: 527
  • Karma: +0/-0
  • You Think I Can't See U
    • View Profile
    • Road2hardCoreIron.net
Arimidex vs Nolvadex
« on: July 11, 2021, 04:48:53 am »
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer
F Boccardo et al. J Clin Oncol. 2005.
Show details


Abstract

Purpose: To determine whether tamoxifen or anastrozole prevents gynecomastia and breast pain caused by bicalutamide (150 mg) without compromising efficacy, safety, or sexual functioning.

Patients and methods: A double-blind, placebo-controlled trial was performed in patients with localized, locally advanced, or biochemically recurrent prostate cancer. Patients (N = 114) were randomly assigned to either bicalutamide (150 mg/d) plus placebo or in combination with tamoxifen (20 mg/d) or anastrozole (1 mg/d) for 48 weeks. Gynecomastia, breast pain, prostate-specific antigen (PSA), sexual functioning, and serum levels of hormones were assessed.

Results: Gynecomastia developed in 73% of patients in the bicalutamide group, 10% of patients in the bicalutamide-tamoxifen group, and 51% of patients in the bicalutamide-anastrozole group (P < .001); breast pain developed in 39%, 6%, and 27% of patients, respectively (P = .006). Baseline PSA level decreased by > or = 50% in 97%, 97%, and 83% of patients in the bicalutamide, bicalutamide-tamoxifen, and bicalutamide-anastrozole groups, respectively (P = .07); and adverse events were reported in 37%, 35%, and 69% of patients, respectively (P = .004). There were no major differences among treatments in sexual functioning parameters from baseline to month 6. Elevated testosterone levels occurred in each group; however, free testosterone levels remained unchanged in the bicalutamide-tamoxifen group because of increased sex hormone-binding globulin levels.

Conclusion: Anastrozole did not significantly reduce the incidence of bicalutamide-induced gynecomastia and breast pain. In contrast, tamoxifen was effective, without increasing adverse events, at least in the short-term follow-up. These data support the need for a larger study to determine any effect on mortality.

Share on Facebook Share on Twitter


 

+-Recent Topics

20 WEEK HGH/IGF1/INSULIN BLAST by ROAD2HARDCOREIRON
October 11, 2021, 07:42:33 pm

SPRECTRUM PRODUCTS BEING MADE by ROAD2HARDCOREIRON
October 11, 2021, 05:46:46 pm

SPECTRUM CATALOG 2021-22 by ROAD2HARDCOREIRON
October 10, 2021, 11:44:06 am

George Peterson found dead by ROAD2HARDCOREIRON
October 07, 2021, 06:38:21 pm

INFORMATION ON ZPHCD HGH by ROAD2HARDCOREIRON
September 18, 2021, 10:28:27 am

Melissa Bumstead Arrested by ROAD2HARDCOREIRON
September 16, 2021, 03:59:28 pm

OMEGA LABS DBOL by ROAD2HARDCOREIRON
September 11, 2021, 06:20:55 pm

What is the Best HGH? by ROAD2HARDCOREIRON
August 31, 2021, 08:22:43 am

What color HGH Top is legit and Best!! by ROAD2HARDCOREIRON
August 31, 2021, 07:54:39 am

How to Set Up Humotrope Pen by ROAD2HARDCOREIRON
August 31, 2021, 06:45:11 am